"Factor Xii (Hageman Factor) (F12), Kallikrein B, Plasma (Fletcher Factor) 1 (Klkb1), And Kininogen 1 (Kng1) Irna Compositions And Methods Of Use Thereof" in Patent Application Approval Process (USPTO 20240076664).

This patent application discusses the development of RNAi compositions and methods for inhibiting thrombosis in individuals at risk of forming blood clots. The invention focuses on targeting genes involved in the contact activation pathway, specifically Factor XII (F12), Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1), and Kininogen 1 (KNG1). Thrombosis, the formation of blood clots, can lead to serious health conditions such as deep venous thrombosis, myocardial infarction, and stroke. The invention aims to provide alternative therapies for individuals suffering from Hereditary Angioedema (HAE), a genetic disorder that dysregulates the balance between procoagulant and anticoagulant forces, resulting in recurrent edema and swelling. The patent application describes double-stranded ribonucleic acid (RNAi) agents for inhibiting the expression of certain genes, including Factor XII (Hageman Factor) (F12), Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1), and Kininogen 1 (KNG1). The RNAi agents consist of a sense strand and an antisense strand, with specific nucleotide sequences that are complementary to the target gene sequences. The agents may also contain modified nucleotides and ligands attached to the sense strand. These RNAi agents can be used to inhibit gene expression in cells and may have potential therapeutic [Extracted from the article]